Pharmaceuticals, Biotechnology and Life Sciences
United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has recruited 50% of the myasthenia gravis (MG) patients in the Phase 2 proof-of-concept study of ARGX-113.
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has initiated a potentially pivotal Phase 2b clinical study of BPS-804 for the treatment of the orphan disease, osteogenesis imperfecta (OI) (brittle bone disease), the ASTEROID study.
CTI BioPharma has reported net loss of $19.8 million for the first quarter of 2017. The loss is decrease compared to the profit of $3.3 million for the same period in 2016.
Swedish Orphan Biovitrum (Sobi) has appointed Guido Oelkers as President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.
Novo Nordisk has reported profit of €1.4 billion for the first quarter of 2017, which is increase of 10%.
Swedish Orphan Biovitrum (Sobi) will open a new office in Athens, Greece.
Novartises Rydapt has been approved by the FDA for the treatment of acute myeloid leukemia, and for treating adults with advanced systemic mastocytosis.
Sanofi Chief Executive Officer, Olivier Brandicourt, said that the company has started the year with robust growth driven by Specialty Care and Vaccines as well as good performance in Emerging Markets.